Spero Therapeutics (NASDAQ:SPRO) announced its earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.49, Fidelity Earnings reports. The company had revenue of $7.72 million during the quarter, compared to analysts’ expectations of $1.25 million. Spero Therapeutics had a negative net margin of 1,050.48% and a negative return on equity of 43.63%.
Shares of NASDAQ:SPRO traded up $1.05 during trading on Friday, reaching $12.43. The stock had a trading volume of 16 shares, compared to its average volume of 73,898. The firm has a market cap of $198.27 million, a PE ratio of -4.60 and a beta of 2.70. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $18.23.
A number of brokerages have issued reports on SPRO. Cantor Fitzgerald restated a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, February 26th. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 26th. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Saturday, March 16th. Finally, TheStreet lowered shares of Spero Therapeutics from a “c-” rating to a “d” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Spero Therapeutics has an average rating of “Hold” and an average target price of $21.80.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/spero-therapeutics-spro-issues-earnings-results.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Read More: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.